Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins

Shares of Vertex Pharmaceuticals Inc. were down 0.2% in trading on Wednesday after the company said it started an early-stage clinical trial for its experimental treatment for people with type 1 diabetes. It also said the therapy received a fast-track designation from the Food and Drug Administration.

Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the company has initiated a clinical trial for VX-880 in patients who have type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness. “This program has its roots in the groundbreaking work that began in Dr. Doug Melton's lab, progressed at Semma Therapeutics, and has been accel

Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes

AbbVie

Bristol-Myers

Novavax

Regeneron Pharmaceuticals

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

Salesforce

These high-growth stocks should handily outperform the most-popular Reddit rally companies.

Forget GameStop, AMC, and Sundial: These Are the Best Stocks to Buy Right Now

Diamond Hill Investment Group

Sprouts Farmers Markets

Avoiding greediness is one of the key factors to generate wealth in the stock market. Therefore, I have abundantly reminded investors about the recent risks in momentum stocks.Over the past few months, we have focused on undiscovered, undervalued stocks instead of betting on momentum. This contrarian approach led to a lot of wealth generation while momentum stocks crashed.

3 Must-Own Anti-Bubble Stocks Insiders Bought Heavily

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?

Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound?

Cowen

Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at Cowen 41st Annual Health Care Conference (Transcript)

Zoom Video

These fast-paced businesses can supercharge investors' portfolios.

3 Growth Stocks That'll Make You Richer in March (and Beyond)

Netflix

The 50-day moving average is one of the most widely respected technical indicators among investors looking for growth stocks and breakouts. The post Use This Chart Tool To Know When To Buy Or Sell Growth Stocks appeared first on Investor's Business Daily.

Use This Chart Tool To Know When To Buy Or Sell Growth Stocks

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET. The audio portion of management's remarks will be available live through Vertex's website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company th

Vertex to Present at the Cowen Health Care Conference on March 2

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

Novartis

Pacific Biosciences of California

Roche Holding AG

Takeda Pharmaceutical

Teladoc

Thermo Fisher Scientific

Twist Bioscience Corp

Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.

ARKG: Precautionary Measures, But Transformational Objectives Remain Intact

The biotech is looking for late-sage drugs to fuel future growth.

What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?

The biotech's revenue and earnings growth were better than the reported results.

Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared

Anthem

Humana

Merck

UnitedHealth Group

With the markets setting all-time highs again and the first quarter soon to begin winding down, investors may be pondering how to position themselves for the rest of the year.

5 Health Care Laggards With Healthy Upside Potential

Invitae

Progyny

Two innovative small companies with scorching growth and one bargain biotech.

3 Healthcare Stocks I'd Buy Right Now

Intellia Therapeutics

Our indicative theme of Gene Editing Stocks is up by about 187% since the end of 2018 and by about 5% year-to-date. Gene editing has received more attention this year, as scientists used the technology to cure progeria syndrome in mice, raising hopes for therapy in humans as well.

Vertex, Intellia Therapeutics: Gene Editing Stocks To Watch

Medtronic

The Vanguard Health Care Fund (Trades, Portfolio) has released its portfolio for the fourth quarter. Major trades include selling out of Medtronic PLC (NYSE:MDT), Merck & Co Inc. (NYSE:MRK) and Roche Holding AG (XSWX:ROG).

The Vanguard Health Care Fund's Top 5 Trades of the 4th Quarter

The stock price of Vertex Pharmaceuticals has seen a decline of 7% over the last five trading days, while it's down 11% over the last ten trading days. This drop can largely be attributed to the company's Q4 results, with EPS missing the consensus estimates.

Vertex Pharmaceuticals Stock Likely To Trend Higher After The Recent 11% Drop

Here's why you should still pick up shares of this high-flying biotech.

3 Reasons It's Not Too Late to Buy Vertex Pharmaceuticals

Apple

Guardant Health Inc

Ignore GameStop: Here Are 3 Better Stocks

Vertex Q4 2020 revenue grew 15% y/y. The pipeline of potential drugs is strong.

Vertex Pharmaceuticals Poised For Long-Term Growth

Investors were not pleased with the company's latest quarterly update.

Why Vertex Pharmaceuticals Stock Fell Today

Analysts applauded Vertex Pharmaceuticals' (NASDAQ:VRTX) fourth-quarter and full-year 2020 results, but voiced skepticism about the company's ability to maintain its momentum.

Despite Outstanding 2020, Vertex Shares Skid

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.

News for Vertex Pharmaceuticals Stock (VRTX)